Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. (ESLAW) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Estrella Immunopharma, Inc. in 2026.
Earnings calendar
Next earnings date
—
Not scheduled
EPS estimate
—
Revenue estimate
—
Past earnings
No earnings history available.
Dividend calendar
No dividend history available.
Company profile
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Exchange
- Nasdaq
- CEO
- Cheng Liu
- ISIN
- US2975841121
- Website
- estrellabio.com
Frequently asked questions
Where is Estrella Immunopharma, Inc. stock listed?
Estrella Immunopharma, Inc. (ESLAW) is listed on Nasdaq.